Severe COVID-19 infection in a kidney transplant recipient treated with lopinavir/ritonavir, hydroxychloroquine and dexamethasone.
J Infect Dev Ctries
; 15(9): 1257-1262, 2021 09 30.
Article
in English
| MEDLINE | ID: covidwho-1478145
ABSTRACT
Severe COVID-19 infection management for a recipient of kidney transplant has debatable prognosis and treatment. We described the case of a COVID-19 infected 70 year old female, previously had renal transplantation in 2017. The patient took immunosuppressive agents as routine drugs for transplant recipient status and received lopinavir/ritonavir, hydroxychloroquine, and dexamethasone daily at the hospitalization. Specific question arises about renal transplant recipients being infected by COVID-19 - whether the infection will get worse compared to those without immunosuppresive agent. In this case, author decided to stop the immunosuppressive agent followed administration of combination lopinavir/ritonavir, hydroxychloroquine, and dexamethasone that gives a good clinical impact change to patient's condition after once getting worsened and mechanically ventilated. Nevertheless, the assessment of risk and benefit in continuing immunosuppressive drugs is concurrently essential due to the prevention of transplant rejection.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Dexamethasone
/
Ritonavir
/
Lopinavir
/
COVID-19 Drug Treatment
/
Hydroxychloroquine
Type of study:
Case report
/
Prognostic study
Limits:
Aged
/
Female
/
Humans
Language:
English
Journal:
J Infect Dev Ctries
Journal subject:
Communicable Diseases
Year:
2021
Document Type:
Article
Affiliation country:
Jidc.14952
Similar
MEDLINE
...
LILACS
LIS